Telesis Bio Inc

Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Sanofi

The company's collaboration with Sanofi is shifting into a higher gear.

Here's Why Translate Bio Stock Is Rocketing Higher Today

Shares of the small-cap mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO) were ripping higher Tuesday.

Why Shares of Translate Bio Are Surging Higher

Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. 
The companies are already developing a mRNA vaccine candidate to combat COVID-19.

Sanofi Expands Agreement With Translate Bio for mRNA Vaccines

Sanofi S.A. (NASDAQ: SNY) and Translate Bio Inc.

Why the Sanofi and Translate Bio Deal Is Win-Win

Translate Bio stock rocketed Tuesday after the biotech inked a deal with Sanofi to develop vaccines for all infectious diseases. Before, the companies had a deal for five vaccines.

Small Biotech Rockets 60% On Sanofi's $425 Million Vaccines Bet

French drugmaker Sanofi has agreed a potential $2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their collaboration in development of an inoculation against COVID-19.

Sanofi clinches $2 billion vaccines deal with Translate Bio

-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases --  -- Translate Bio to receive $425 million in upfront payment and common stock equity investment and overall is eligible to receive up to $1.9 billion of potential milestones/payments as well as tiered royalties on worldwide sales of developed vaccines --

Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas

BioNTech SE

Moderna

The race for a coronavirus vaccine is giving biotech companies like Moderna, BioNTech and Translate Bio the chance to prove a relatively new technology known as messenger RNA vaccines.
The post How The Coronavirus Pandemic Could Give Rise To A New Type Of Vaccine appeared first on Investor's Business Daily.

How The Coronavirus Pandemic Could Give Rise To A New Type Of Vaccine

As of late, it has definitely been a great time to be an investor of Translate Bio

Will Translate Bio Continue to Surge Higher?

LEXINGTON, Mass., May  12, 2020  (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.

Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference

Sanofi’s (NASDAQ:SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.

Translate Bio Boosted by Sanofi Vaccine Agreement

-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur --    -- Existing large-scale manufacturing capacity expected to help meet needs of pandemic --

Translate Bio Announces First Quarter 2020 Financial Results and  Provides Corporate Update

Translate Bio Inc (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Translate Bio Inc (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Atara Biotherapeutics

Biohaven Pharmaceutical Hld

CymaBay Therapeutics

Marinus Pharmaceuticals

PTC Therapeutics

Solid Biosciences

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

7 Disruptive Biotech Stocks to Buy for 2025

Shares of Lexington, Massachusetts-based biotechnology company Translate Bio Inc.

Sanofi Partners With Translate Bio on Covid-19 Vaccine

AstraZeneca

GlaxoSmithKline

Pfizer

Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.

Is mRNA the Key to a Coronavirus Vaccine?

CRISPR Therapeutics

Gilead Sciences

Johnson & Johnson

Regeneron Pharmaceuticals

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher

Translate Bio's messenger RNA technology will make the development process faster than the traditional methods.

Sanofi and Translate Bio Team Up to Work on a Coronavirus Vaccine

Translate Bio stock popped Friday after the biotech company inked a deal with Sanofi to develop a coronavirus vaccine using messenger RNA. The two companies began partnering in 2018.

Covid Report: Small Biotech Pops On Sanofi Deal For Coronavirus Vaccine

The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development

Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –

Translate Bio Provides MRT5005 Program Updates

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -33.33% and 27.00%, respectively, for the quarter ended December 2019.

Translate Bio, Inc. (TBIO) Reports Q4 Loss, Tops Revenue Estimates

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

News for Telesis Bio Inc Stock (TBIO)